Reversibility of the effect of LHRH agonists and other antiandrogenic hormones on the testis: a histomorphometric study.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 2127019.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Changes in testicular morphology are quantified in patients with metastatic prostatic cancer, treated with LHRH agonist Buserelin and compared with testes of young transsexuals and patients with metastatic prostatic cancer treated with orchidectomy only. No significant changes within 18 months were seen, suggesting reversibility of LHRH agonist effects on testicular morphology in this time period. Histomorphometrics of the testis are useful to quantify these changes.
Medical subject headings
- Buserelin
- Prostatic Neoplasms
- Testis